Latest Revenue Growth News

Farm Pride Foods Ltd reported a 16% revenue increase to $118.3 million and a 53% jump in net profit to $10.2 million for FY26, underpinned by operational improvements and strategic capital investments.

IMEXHS Limited has swung to a profit of $66,200 in 1H FY26, driven by a 17% revenue increase and a surge in underlying EBITDA to $1.27 million. The company’s AI-native radiology platform and Latin American partner expansion underpin growth amid ongoing sector liquidity challenges.

Cobram Estate Olives (ASX:CBO) posted an 11.3% revenue increase to A$268.9 million in FY2026 but swung to a A$4.2 million net loss as costs surged and integration expenses weighed. The company declared a steady fully franked dividend of 4.5 cents per share.

Dicker Data’s first half FY26 results reveal a sharp 54% jump in net profit, driven by strong revenue growth across software and AI infrastructure, prompting an upgraded full-year forecast.

Resonance Health (ASX: RHT) reported a profitable turnaround in FY26, driven by growth across its imaging software, clinical trial services, and site network businesses.

CleanSpace Holdings is set to repurchase up to 10% of its shares over the next year, signalling confidence in its growth prospects and capital position.

Ashley Services Group delivered a standout FY26 with revenue up 16.7% to $602.2 million and net profit after tax surging 189.5% to $6.29 million, supported by margin gains across key sectors and a strategic acquisition.

Immuron Limited posted a 6% rise in FY26 sales to $7.7 million, improved its net loss by $1.4 million, and secured FDA approval for IMM-529, underpinning a strategic pivot towards profitability and geographic expansion.

PEXA Group delivered a solid FY26 with 7% revenue growth and a return to profitability, while facing a regulatory pricing review that could reshape its future investment capacity.

SomnoMed reported a 3% revenue rise to $114.5 million and a 19% EBITDA increase to $10.9 million in FY26, navigating European market headwinds and a CEO transition while launching its Virtus device targeting sleep apnea with bruxism.

ECS Botanics boosted revenue by 10% to $21.4 million in FY26, delivering positive EBITDA and operating cash flow while advancing international market entry and branded product growth.

Saluda Medical delivered FY26 revenue of US$90.2 million, beating guidance with strong US and international growth, while reporting a flat net loss of US$149.6 million amid ongoing heavy investment. The company’s FDA approval of its CAP24 paddle lead opens a new US surgical market segment.